April 29, 2026 HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026 Auddia Highlights $12M Financing as Catalyst to Unlock Distributed AI Datacenter Value Through Merger Acceleration